Apollo Hospitals Enterprise Ltd. Upgraded to Strong Buy on Robust Financial and Technical Performance

Financial Performance Drives Upgrade

The primary catalyst behind the rating upgrade is Apollo Hospitals’ very positive financial trend observed in the quarter ended June 2026. The company’s financial grade improved from a positive 17 to a very positive 20 over the last three months, signalling enhanced operational efficiency and profitability. Key financial metrics reached record highs, underscoring the company’s robust earnings momentum.

Return on Capital Employed (ROCE) for the half-year stood at an impressive 17.41%, reflecting efficient utilisation of capital to generate profits. Net sales for the quarter surged to ₹7,043.50 crores, the highest recorded, while operating profit to interest coverage ratio reached 9.07 times, indicating strong ability to service debt obligations. The company’s PBDIT (Profit Before Depreciation, Interest and Taxes) hit ₹1,092.10 crores, and Profit Before Tax (excluding other income) was ₹750.00 crores, both all-time highs.

Net profit after tax (PAT) also rose to ₹580.70 crores, with operating profit to net sales ratio improving to 15.51%. Earnings per share (EPS) for the quarter reached ₹40.38, marking a significant increase. Notably, there were no key negative triggers identified in the financials, reinforcing the company’s stable earnings quality.

Over the longer term, Apollo Hospitals has demonstrated consistent growth with net sales expanding at an annual rate of 16.82% and operating profit growing at 23.85%. The company has declared positive results for 11 consecutive quarters, highlighting sustained operational strength. Its return on equity (ROE) stands at 20.63%, further confirming management’s effectiveness in generating shareholder value.

Valuation Becomes More Attractive

The valuation grade for Apollo Hospitals has been upgraded from fair to attractive, reflecting a more favourable price entry point for investors. The company currently trades at a price-to-earnings (PE) ratio of 60.99, which, while elevated, is reasonable given its growth prospects and sector leadership. Its price-to-book value stands at 13.54, and enterprise value to EBIT and EBITDA ratios are 43.27 and 33.59 respectively.

Importantly, the enterprise value to capital employed ratio is a modest 8.50, signalling efficient capital utilisation relative to market valuation. The PEG ratio of 1.81 indicates that the stock’s price reasonably reflects its earnings growth potential. Dividend yield remains modest at 0.34%, consistent with the company’s reinvestment strategy for growth.

Compared to peers such as Manipal Health, which is classified as very expensive with a PE of 101.52, Apollo Hospitals offers a more attractive valuation proposition. This discount relative to sector peers enhances its appeal for long-term investors seeking quality exposure in the hospital and healthcare services industry.

Technical Indicators Signal Bullish Momentum

The technical trend for Apollo Hospitals has improved from mildly bullish to bullish, supporting the upgrade in investment rating. Key technical indicators present a predominantly positive outlook across multiple timeframes. The Moving Average Convergence Divergence (MACD) is bullish on both weekly and monthly charts, signalling upward momentum.

While the Relative Strength Index (RSI) on the weekly chart shows a bearish signal, the monthly RSI remains neutral, suggesting room for further price appreciation without being overbought. Bollinger Bands indicate mild bullishness on weekly and monthly scales, and daily moving averages confirm a bullish trend.

Additional momentum indicators such as the Know Sure Thing (KST) oscillator are bullish on both weekly and monthly charts. Dow Theory analysis is mildly bearish weekly but bullish monthly, reflecting short-term consolidation within a longer-term uptrend. On-Balance Volume (OBV) is mildly bearish weekly but mildly bullish monthly, indicating mixed but generally positive volume support.

These technical signals, combined with strong fundamentals, provide a solid foundation for the stock’s upgraded rating and recent price appreciation, with the stock closing at ₹8,925 on 17 Aug 2026, up 3.84% from the previous close of ₹8,595.

Quality and Market Position Remain Strong

Apollo Hospitals maintains a high-quality grade, reflected in its MarketsMojo Mojo Score of 84.0 and a Mojo Grade of Strong Buy, upgraded from Buy on 14 Aug 2026. The company is classified as a large-cap stock with a market capitalisation of ₹1,28,328 crores, making it the largest player in the hospital sector, representing 16.94% of the entire industry.

Its annual sales of ₹26,429.90 crores constitute nearly a quarter (24.91%) of the hospital and healthcare services sector, underscoring its dominant market position. Institutional holdings are robust at 65.44%, indicating strong confidence from sophisticated investors with the resources to analyse fundamentals deeply.

Over the past decade, Apollo Hospitals has delivered an extraordinary 530.07% return, vastly outperforming the Sensex’s 177.10% gain. Even in the last year, the stock returned 14.12% compared to the Sensex’s decline of 3.21%, while profits surged 33.7%, highlighting the company’s resilience and growth trajectory.

Outlook and Investment Implications

The upgrade to Strong Buy reflects a confluence of factors that make Apollo Hospitals an attractive investment opportunity. Its very positive financial trend, highlighted by record quarterly sales and profits, demonstrates operational excellence and growth sustainability. The improved valuation metrics suggest the stock is reasonably priced relative to its earnings growth and sector peers.

Technically, the stock exhibits bullish momentum across key indicators, supporting further upside potential. The company’s dominant market position, high institutional ownership, and consistent track record of positive quarterly results for nearly three years reinforce its quality credentials.

Investors seeking exposure to the hospital and healthcare services sector may find Apollo Hospitals a compelling large-cap choice, combining growth, quality, and relative valuation attractiveness. While the stock trades near its 52-week high of ₹9,326.80, the strong fundamentals and technical signals suggest room for further appreciation.

Given the absence of any key negative triggers and the company’s ability to generate healthy returns on capital, the upgraded rating to Strong Buy by MarketsMojo is well justified. This upgrade also places Apollo Hospitals among the top 1% of companies rated across over 4,000 stocks, ranking 3rd among large caps and 24th overall in the market.

Summary of Key Metrics

Financial Highlights (Q1 FY26-27):

• ROCE (Half Year): 17.41%
• Net Sales (Quarterly): ₹7,043.50 crores
• Operating Profit to Interest Coverage: 9.07 times
• PBDIT: ₹1,092.10 crores
• PBT (excl. other income): ₹750.00 crores
• PAT: ₹580.70 crores
• Operating Profit to Net Sales: 15.51%
• EPS: ₹40.38

Valuation Metrics:

• PE Ratio: 60.99
• Price to Book Value: 13.54
• EV to EBIT: 43.27
• EV to EBITDA: 33.59
• EV to Capital Employed: 8.50
• PEG Ratio: 1.81
• Dividend Yield: 0.34%

Technical Indicators:

• MACD: Weekly & Monthly Bullish
• RSI: Weekly Bearish, Monthly Neutral
• Bollinger Bands: Mildly Bullish (Weekly & Monthly)
• Moving Averages: Daily Bullish
• KST: Weekly & Monthly Bullish
• Dow Theory: Weekly Mildly Bearish, Monthly Bullish
• OBV: Weekly Mildly Bearish, Monthly Mildly Bullish

Conclusion

Apollo Hospitals Enterprise Ltd.’s upgrade to a Strong Buy rating is underpinned by its stellar financial results, improved valuation appeal, and strengthening technical outlook. The company’s leadership in the hospital sector, combined with consistent earnings growth and high institutional confidence, makes it a standout large-cap stock for investors seeking quality and growth. While the stock has already delivered strong returns over multiple time horizons, the current assessment suggests further upside potential, making it a key portfolio consideration in the healthcare space.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today